Seres Therapeutics Inc SER-109 Co-Commercialization License Agreement Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Seres Therapeutics Business Update Conference Call. (Operator Instructions) Please be advised that this conference call is being recorded. I would now like to hand the conference over to your speaker for today, Dr. Carlo Tanzi of Investor Relations. Carlo, please go ahead.
Thank you, and good morning. A press release announcing that Seres has entered into a license agreement with Nestlé Health Science, who we'll be referring to as Nestlé, to co-commercialize SER-109 became available at 7:00 a.m. Eastern Time this morning and can be found on the Investors & News section of the company's website.
I'd like to remind you that we'll be making forward-looking statements relating to the timing, enrollment and results of our clinical studies, regulatory approval, the promise and potential impact of SER-109, including the potential market size, any potential benefits of collaborating with Nestlé, potential
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |